Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as RSV vaccine GSK3003892A (formulation 1)
RSV vaccine GSK3003892A · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group A | EXPERIMENTAL | Subjects in this group will receive a single dose of formulation 1 of RSV vaccine |
| Group B | EXPERIMENTAL | Subjects in this group will receive a single dose of formulation 2 of RSV vaccine |
| Group C | EXPERIMENTAL | Subjects in this group will receive a single dose of formulation 3 of RSV vaccine |
| Group D | EXPERIMENTAL | Subjects in this group will receive a single dose of formulation 4 of RSV vaccine |
| Group E | EXPERIMENTAL | Subjects in this group will receive a single dose of formulation 5 of RSV vaccine |
| Group F | EXPERIMENTAL | Subjects in this group will receive a single dose of formulation 6 of RSV vaccine |
| Group Placebo 1 | PLACEBO_COMPARATOR | Subjects in this group will receive a single dose of placebo |
| Group Placebo 2 | PLACEBO_COMPARATOR | Subjects in this group will receive a single dose of placebo |
| Name | Type | Description |
|---|---|---|
| RSV vaccine GSK3003892A (formulation 1) | BIOLOGICAL | Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule |
| RSV vaccine GSK3003893A (formulation 2) | BIOLOGICAL | Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule |
| RSV vaccine GSK3003895A (formulation 3) | BIOLOGICAL | Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule |
| RSV vaccine GSK3003896A (formulation 4) | BIOLOGICAL | Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule |
| RSV vaccine GSK3003898A (formulation 5) | BIOLOGICAL | Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule |
| RSV vaccine GSK3003899A (formulation 6) | BIOLOGICAL | Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule |
| Placebo comparator | DRUG | Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule |
Inclusion Criteria: * Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol. * Written informed consent obtained from the subject. * A male between, and including, 18 and 44 years of age at the time of vaccination. * Healthy subjects as establis...
RSV vaccine GSK3003892A is an investigational vaccine developed by GSK plc for the prevention of respiratory syncytial virus (RSV) infections. It is a vaccine candidate that has been studied in a Phase 1 clinical trial. The vaccine is designed to protect against RSV, a common respiratory virus that can cause serious illness.
RSV vaccine GSK3003892A is being developed for the prevention of infections caused by respiratory syncytial virus (RSV). RSV is a major cause of respiratory illness. The vaccine is intended for use in adults, as the clinical trial enrolled male participants aged 18 years and older.
RSV vaccine GSK3003892A is being developed by GSK plc, a global pharmaceutical company. GSK plc is listed on the New York Stock Exchange under the ticker symbol GSK. The company is responsible for the research and clinical development of this investigational RSV vaccine candidate.
RSV vaccine GSK3003892A is in Phase 1 clinical development. The Phase 1 trial has been completed. As an investigational vaccine, it has not been approved by the FDA or any regulatory authority. Further clinical trials would be needed to establish its safety and efficacy.
RSV vaccine GSK3003892A has been evaluated in a Phase 1 clinical trial, NCT01905215, titled 'Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccines.' The trial was completed and enrolled 128 participants in Canada. It was randomized, double-blind, and placebo-controlled.
Yes, RSV vaccine GSK3003892A is also known as RSV vaccine GSK3003892A (formulation 1). The parenthetical designation distinguishes this specific formulation from other formulations that may be studied under the same base name. Both names refer to the same investigational vaccine candidate developed by GSK plc.